Press Release

Huntington Study Group Annual Meeting

Rochester, NY November 29, 2022 – The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD), recently held its 29th Annual Meeting in Tampa, FL. This renowned meeting brings together HD thought leaders, scientific experts, industry partners and sponsors, advocacy groups, and HD family and community members from around the world.

At this year’s meeting, attendees heard about exciting clinical trial advancements including gene therapies, biomarkers (e.g., PET Imaging of Synapses and Mutant Huntingtin), and updates regarding the development and progress of novel tools being used to improve research and care (e.g., HSG’s® and myHDstory™ observational studies). These presentations and other inspiring talks raised hope for the whole HD community of patients, families, clinicians, and researchers.

“The plenary sessions at the Huntington Study Group 2022 Annual Meeting in Tampa were truly some of the best I can remember! I was particularly excited by the session on imaging and tissue biomarkers and also the Innovator’s Forum, which brought together a large number of early-stage therapeutics companies focused on preclinical drug development for HD,” said Jody Corey-Bloom, MD, PhD, Neurologist at UC San Diego and member of HSG.

Christopher Ross, MD, PhD Chief Scientific Officer at HSG, said “Interestingly, small molecules (i.e., drugs that can be taken orally) seem to be undergoing a bit of resurgence. It’s great to see that there are studies of so many approaches to treating HD.”

At the meeting, HSG announced more details about their expanded clinical trial operations. The organization offers a full suite of Clinical Research Organization (CRO) services including Global Trial Operations, Advisory Boards, and Protocol Design and Review. For 29 years, the HSG has been leveraging the expertise, innovation, and commitment of their members and staff to set the gold standard for running HD clinical trials. The HSG’s dedication to its mission – seeking treatments that make a difference – has never been stronger. 

Shari Kinel, JD, CEO of Huntington Study Group noted, “After holding the meeting remotely for the past two years due to COVID, the joy and excitement we all felt from being back together in person was palpable. We are truly grateful to all of our attendees, the HD community, and to everyone who helped make this event a remarkable success.”

Next year, HSG will celebrate its 30th Anniversary at their 2023 Annual Meeting.

About Huntington’s Disease
Huntington’s Disease (HD) is a hereditary neurodegenerative disease characterized by a movement disorder, psychiatric difficulties, and cognitive changes, usually beginning in middle adult life. About 40,000 people in North America have HD, and another 200,000 are considered “at risk” for inheriting the illness because they have (or had) a parent with HD.
 
About Huntington Study Group / HSG Clinical Research
Founded in 1993 in Rochester, NY, the Huntington Study Group (HSG) is a not-for-profit organization comprised of the world’s first and largest collaborative network of experts in Huntington’s Disease whose mission is to seek treatments that make a difference for those affected by HD. HSG Clinical Research, Inc., a wholly owned subsidiary of the HSG, is a full-service clinical research organization that specializes on conducting trials in HD. There are over 800 HD experts at more than 130 HSG credentialed research sites worldwide. The HSG also offers educational services like CME4HD™ for healthcare professionals and care providers on treating patients with HD. For more information, visit www.huntingtonstudygroup.org.

View full press release.

Huntington Study Group Announces Results from the HD-Net Assessment on the State of Care for Huntington’s Disease in the United States

Rochester, NY  October 25, 2022 — The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce the results from the novel HD-Net survey, which examined the United States Huntington’s disease (HD) care delivery in a variety of clinic settings by HD specialists and non-specialists.

“The importance of this research survey is the real-world sampling of HD care across all types of medical practices in the United States and how it shows us the inequality in care levels with different practice types. This is a call for us to increase outreach and education to those practices who are already seeing HD patients to improve care and access to specialty services,” said Lauren Seeberger, MD, HD-Net Principal Investigator and Associate Professor at the University of Colorado.

The HSG collaborated with the University of Colorado, University of California San Diego, Genentech, Inc., and RAND Corporation, to make this novel survey accessible for qualifying United States residents to access. The HD-Net is obtained a clearer understanding of current care structure and delivery of care through a survey of representative US physicians treating HD patients. The survey included 40 closed-ended evaluative items and one open-ended item to a sample of 339 US practices. Unique to this survey was the inclusion of non-specialists. Findings concluded that HD care was inconsistently applied across the US. Practices led by neurologists trained in movement disorders, and higher HD volume practices, tended to be better equipped to provide multi-disciplinary staffing and procedures as compared to those with fewer numbers of HD patients.

“We would like to thank Lauren Seeberger, MD; Jody Corey-Bloom, MD, PhD; Michael O’Brien; Diana Slowiejko, PharmD, PhD; Danielle Schlang, MA; Marika S. Booth, MS; Beth Ann Griffin, PhD; and Peggy G. Chen, MD, MSc, MHS for their work on HD-Net,” said Shari Kinel, JD, Chief Executive Officer of the Huntington Study Group. “The HSG would also like to extend our appreciation to Diana Slowiejko, PharmD, PhD, the Principal Med Science Director of Genentech, for her pivotal role in project development and support.

Acknowledgment
Acknowledgment to the HD-Net Steering Committee (Donald Higgins MD, Samuel S. Stratton VA Medical Center, Albany, New York; Joseph Jankovic MD, Baylor College of Medicine, Houston, Texas; Jamie Levey, MBA, CHDI Foundation; Karen Marder MD, MPH, Columbia University Medical Center, New York, New York; Julie Parsons MD, Children’s Hospital Colorado, Aurora, Colorado; Abdul R Shaikh, PhD, Guidehouse, Washington, DC; Emily Troncoso; Louise Vetter, Huntington’s Disease Society of America, New York, New York); and for the generous support from Genentech, Inc.

For more information about HD-Net, visit https://huntingtonstudygroup.org/hd-net/.

About Huntington’s Disease
Huntington’s Disease (HD) is a hereditary neurodegenerative disease characterized by a movement disorder, psychiatric difficulties, and cognitive changes, usually beginning in middle adult life. About 40,000 people in North America have HD, and another 200,000 are considered “at risk” for inheriting the illness because they have (or had) a parent with HD. 

About Huntington Study Group / HSG Clinical Research
Founded in 1993 in Rochester, NY, the Huntington Study Group (HSG) is a not-for-profit organization comprised of the world’s first and largest collaborative network of experts in Huntington’s Disease whose mission is to seek treatments that make a difference for those affected by HD. HSG Clinical Research, Inc., a wholly owned subsidiary of the HSG, is a full-service clinical research organization that specializes on conducting trials in HD.  There are 700 credentialed HD experts at more than 120 HSG credentialed research sites worldwide.  The HSG also offers educational services like CME4HD ™ for healthcare professionals and care providers on treating patients with HD. For more information, visit www.huntingtonstudygroup.org.

About HD-Net
The HD-Net Community was formed in 2019 through funding by Genentech, managed by the Huntington Study Group (HSG) and supported by leaders of the HD community – CHDI, HDSA and others. HD-Net is committed to elevating the level of HD care and bridging the gaps that exist in the access to that care. HD-Net’s initial focus is to improve care, deepen HD knowledge, provide resources, emphasize the patient, harness technology, and support new therapies.

View full press release.

Huntington Study Group Announces myHDstory™ Pilot Study:  Making HD Voices ­­­Heard Has Reached Target Enrollment

Rochester, N.Y.  October 18, 2022 — The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce that the pilot study, Making HD Voices Heard, on the new online research platform, myHDstory™, has reached its enrollment target. 

“The HSG is beyond thrilled by the level of participation in this first-of-its-kind study. We are extremely grateful to all the participants who enrolled,” said Dr. Karen Anderson, Professor of Psychiatry and Neurology at Georgetown University Medical Center and Principal Investigator of the Making HD Voices Heard study. “We hope the data and lessons learned from this pilot will inform and drive further virtual studies that will engage larger segments of the Huntington’s Disease (HD) population, family members, and caregivers, thereby improving overall development of HD care and treatments,” said Ira Shoulson, MD, Professor of Neurology at the University of Rochester and founder of Grey Matter Technologies, now a wholly owned subsidiary of Modality.ai.

The HSG collaborated with technology companies Grey Matter Technologies and Neurotargeting LLC, to make this novel online research study accessible for qualifying United States residents to access. The myHDstory™ platform is intended to capture longitudinal data on Huntington’s disease from the patient perspective, giving voice to consenting adults to report what they feel, experience, and how they function with Huntington’s disease. This research platform is a significant opportunity for the HSG to serve the HD community because myHDstory™ enables collection of data from patients about their symptoms, without having to schedule in-office visits.
 
“We thank the Griffin Foundation, NJ Cure HD, Ira and Josie Shoulson, Elise Kayson-Rubin, and Richard Rubin for their financial support of myHDstory,” said Shari Kinel, Chief Executive Officer of the Huntington Study Group. “The HSG would also like to extend our appreciation to advocacy groups who helped raise awareness of the pilot study, including Help 4 HD, Huntington’s Disease Youth Organization (HDYO), HD Reach, and Huntington’s Disease Society of America (HDSA).” 

For more information about myHDstoryTM, visit https://huntingtonstudygroup.org/myhdstory/  

About Huntington’s Disease

Huntington’s Disease (HD) is a hereditary neurodegenerative disease characterized by a movement disorder, psychiatric difficulties, and cognitive changes, usually beginning in middle adult life. About 40,000 people in North America have HD, and another 200,000 are considered “at risk” for inheriting the illness because they have (or had) a parent with HD. 

About Huntington Study Group / HSG Clinical Research

Founded in 1993 in Rochester, NY, the Huntington Study Group (HSG) is a not-for-profit organization comprised of the world’s first and largest collaborative network of experts in Huntington’s Disease whose mission is to seek treatments that make a difference for those affected by HD. HSG Clinical Research, Inc., a wholly owned subsidiary of the HSG, is a full-service clinical research organization that specializes on conducting trials in HD.  There are 700 credentialed HD experts at more than 120 HSG credentialed research sites worldwide.  The HSG also offers educational services like CME4HD™ for healthcare professionals and care providers on treating patients with HD. For more information, visit www.huntingtonstudygroup.org.

About Neurotargeting

Neurotargeting was founded in 2007 by Pierre-Francois D’Haese, PhD., Benoit Dawant, PhD. and Peter Konrad, M.D PhD. Neurotargeting, LLC emerged from more than a decade of research performed at Vanderbilt University and supported by NIH funding focused on solving such issues. From this research emerged a unique system called Cranial vault, connecting some of the active groups researching the new potential of DBS such as Vanderbilt University, Ohio State University, Wake Forest University, and the VA in Richmond. With a unique research relationship with its partners, Neurotargeting has built a disruptive software platform. By linking care providers, neuroscience centers and device manufacturers, Neurotargeting aims at improving patients’ care experience and life.

About Modality.ai

Modality.ai is a digital health startup, which acquired Grey Matter Technologies in June 2022. Grey Matter was founded in January 2017 by Ira Shoulson, MD and Carol A Christopher, PhD, who had worked together for nearly three decades to advance innovative medical products for patients with neurological and developmental disorders. Grey Matter’s founders, management team and advisors have long recognized the unmet need to harness the power of the patient’s story, typically told verbatim in unstructured language. Together with the Modality.ai team, they are leading the application of data science technologies aimed at Making Patients Heard™ in healthcare and clinical research settings.

View full press release.

1 2